Oncimmune sells its diagnostic business to Freenome for £13 million
LONDON, UK: Oncimmune Holdings has sold its diagnostic business, including the EarlyCDT® Lung blood test and antibody platform, to Freenome Holdings, a US-based biotechnology company developing a multiomics platform for early cancer detection and intervention. The deal is worth £13M…